Erythropoiesis-stimulating agents (eg, epoetin alfa) are the primary treatment for anemia in patients with end-stage renal disease. Hemoglobin variability in and out of a narrow target range is common and associated with higher morbidity and mortality risk. More robust erythropoiesis-stimulating agent response metrics are needed to define optimal dosing and their association with clinical outcomes. In this cross-sectional, single-center, retrospective study, 49 patients with end-stage renal disease on hemodialysis were followed over 12 months. To quantify hemoglobin deviations outside the target range (10-12 g/dL), the area under the curve of hemoglobin versus time over a 12-month period (AUC-HGB) was calculated using the trapezoidal rule. Patients were categorized into 4 responder groups based on AUC-HGB quartiles. Comparative analyses of demographic and clinical characteristics between responder groups were performed.Correlations between AUC-HGB,erythropoietin resistance index,and time within therapeutic range were calculated. There were no significant differences in laboratory and dialysis parameters between responder groups except hemoglobin concentration and epoetin alfa dose. There was a negative correlation between AUC-HGB and time within therapeutic range (r = -.92; P < .001) and hemoglobin concentration (r = -.85; P < .01), indicating internal validity of the metric. There was a positive correlation between AUC-HGB and erythropoietin resistance index (r = .70; P < .001) indicating external validity. The poor response group received a higher median epoetin alfa dose (160 U/kg/week) compared to the excellent response group (68.8 U/kg/week; P < .001) with a similar number of dose changes between the groups. AUC-HGB is a valid marker of epoetin alfa response and should be considered in future analyses of larger populations.
Erythropoiesis-stimulating agents are first-line treatments for anemia in patients with end-stage renal disease (ESRD). 1 Their clinical use is complex given their delayed onset of action (2-6 weeks) and highly variable drug responses. 2, 3 Although hemoglobin is the gold standard biomarker for evaluating erythropoiesisstimulating agent response, the target hemoglobin for erythropoiesis-stimulating agents is not well defined. Large-scale clinical trials and meta-analyses have indicated an increased risk of vascular access thrombosis, stroke, and hypertension with higher hemoglobin targets. [4] [5] [6] [7] [8] [9] Based on these trials, US and international guidelines and regulatory agencies have made different target hemoglobin recommendations over the past decade ranging from 10 to 12 g/dL. [10] [11] [12] [13] [14] The goal of defining a narrow hemoglobin target window is to minimize thrombotic risks associated with concentrations above the upper limit while preventing the need for blood transfusions and improving quality of life associated with concentrations below the lower limit. Hemoglobin is routinely monitored in ESRD patients to inform erythropoiesis-stimulating agent dosing. While some sophisticated algorithms to assist with erythropoiesis-stimulating agent dosing exist, most clinical dosing approaches are empiric and associated with hemoglobin variability. 15 As a result, clinicians often adjust erythropoiesis-stimulating agent doses reactively in response to hemoglobin fluctuations that cycle outside either end of the target window. This hemoglobin variability is independently associated with mortality. 3, 16 Hemoglobin response can be defined as "in range" or "out of range" at any given point in time. Characterized over a period of time, this "time within therapeutic range" is often regarded as a clinical benchmark for erythropoiesis-stimulating agent response. 17 Currently, the magnitude of hemoglobin deviation from the target range and the time the hemoglobin value is out of range are not quantified in a meaningful manner. Therefore, hemoglobin response metrics need to be redefined beyond the current dichotomous dogma to better guide erythropoiesis-stimulating agent dosing and improve clinical outcomes.
The erythropoietin resistance index was developed as a robust metric of erythropoiesis-stimulating agent resistance and includes the mean weight-adjusted erythropoiesis-stimulating agent dose and mean hemoglobin over a defined period of time. While higher erythropoietin resistance index values are associated with increased mortality, 18 it has been argued that erythropoietin resistance index simply represents a surrogate of the erythropoiesis-stimulating agent dose. 19 This temporal, quantitative metric represents progress, but newer and more informative metrics of response (ie, hemoglobin) need to be evaluated.
The objective of this study was to characterize and quantify the temporal erythropoiesis-stimulating agent response and hemoglobin variability in a crosssectional study of ESRD patients. The goal was to define and validate a new metric for assessing erythropoiesis-stimulating agent response and to determine associations between covariates and hemoglobin variability to help optimize anemia management in ESRD.
Methods

Study Design
The University at Buffalo Institutional Review Board approved the study protocol. Informed consent was not obtained because of the retrospective nature. This was a cross-sectional, single-center, retrospective study of patients with ESRD receiving chronic hemodialysis between April 2014 and April 2015. The 1-year study period was selected to adequately characterize 6 erythrocyte life spans (approximately 60 days in ESRD) and be consistent with previous investigation of hemoglobin variability. 15, 20 The study took place at the outpatient hemodialysis center at Erie County Medical Center in Buffalo, New York. This is a tertiary care teaching hospital in an urban setting.
Study Population
The study population was selected based on the following criteria: (1) ࣙ18 years of age; (2) patients with ESRD receiving chronic intermittent hemodialysis treatments; and (3) the consistent use of epoetin alfa during the study period.
Data Source and Collection
Data were collected from an electronic medical record system at the outpatient dialysis center. For each patient, the following clinical data were collected into a standardized database: (1) basic demographic data (sex, age, ethnicity, weight, and height); (2) past medical history (comorbid conditions, concomitant medications, cause of ESRD, red blood cell transfusion history, and hospitalizations); (3) laboratory values (metabolic panel, complete blood counts, serum B 12 , iron panel, folic acid, and parathyroid hormone); and (4) epoetin alfa and iron dosing administration records. Laboratory parameters were analyzed in the Clinical Laboratory Improvement Amendments certified clinical laboratory at Erie County Medical Center.
For quality assurance and control, investigators with training and experience with the medical record system collected the data. An independent investigator verified a random 10% of the data. Data were further visualized through graphics to detect missing or out-ofrange values and logical inconsistencies. Any potential errors were relayed to an independent investigator, with subsequent validation of the data from the original source.
Erythropoiesis-Stimulating Agent Response Metrics Analysis
A hemoglobin deviation outside the target range of 10 to 12 g/dL was defined as half of 1 hemoglobin cycle (positive [0-180˚] or negative [180-360˚] half cycle of a sinusoidal wave; specific to each patient) outside the target range. To determine the duration and extent of hemoglobin deviation outside the target range, the area under the curve of hemoglobin vs time over a 12-month period (AUC-HGB) was calculated using the trapezoidal rule in R version 3.3.3 ( Figure 1A ). Subjects were then divided into quartiles (first through fourth) based on the calculated AUC-HGB: Quartile 1 included patients with the lowest AUC-HGB and therefore highest proportion of hemoglobin values within the target range, and quartile 4 included patients with the highest AUC-HGB and lowest proportion of hemoglobin values within the target range. Patients moderately responsive to epoetin alfa were placed in the second and third quartiles, where hemoglobin deviations were apparent either above or below the target range. The patients in the first (lowest), second, third, and fourth quartiles were classified as excellent, good, fair, and poor responder groups, respectively. Comparative analyses of the number of hemoglobin deviations outside the target range, duration, and amplitude outside the target range (through AUC-HGB) were performed between responder groups. Additionally, the demographics, clinical characteristics, and laboratory test results were further compared between responder groups.
The erythropoietin resistance index was calculated for each 3-month period as the mean weekly epoetin alfa dose normalized to body weight divided by the mean hemoglobin concentration during that time period. 19 Time within therapeutic range was calculated using the Rosendaal linear interpolation method that was developed to determine the duration of international normalized ratio maintained within the therapeutic range for warfarin therapy in large clinical trials.
21,22
Study End Points
The study objectives were to (1) create and validate a novel characterization of epoetin alfa response, and (2) determine the factors that are associated with this novel metric in ESRD patients. The primary end point was the rate and extent of change in hemoglobin in response to the epoetin alfa dose (ie, the AUC-HGB). Secondary end points were the erythropoietin resistance index and time within therapeutic range.
Statistical Analysis
Descriptive statistics were applied for quantitative variables. Frequency expressed as a percentage described categorical variables while mean ± standard deviation or median (interquartile range [IQR]) described parametric or nonparametric continuous variables, respectively. Kruskal-Wallis and chi-squared tests were performed to assess continuous and categorical variables, respectively, among different response groups. Potential associations between epoetin alfa response metrics and explanatory variables were assessed using linear regression with Spearman's correlation coefficients. All tests were 2-tailed and P-values <.05 were considered statistically significant. Statistical analyses were performed using R 3.3.3 (R Foundation for Statistical Computing, Vienna, Austria) and SPSS Statistics 23.0 (IBM Inc., Chicago, Illinois).
Results
Study Population
Forty-nine patients (29 males and 20 females, age 58.0 ± 13.1 years) were included. The patient demographics and baseline characteristics by responder groups (ie, excellent, good, fair, and poor responder) are summarized in Table 1 . Overall, mean hemoglobin was 10.4 ± 0.58 g/dL with a maximum of 13.6 g/dL and minimum of 6 g/dL. The median (IQR) weight-adjusted epoetin alfa dose was 160 (74.4-370) units/kg/week. A total of 45 patients (90%) received intravenous (IV) iron at least once during the study period. The median (IQR) monthly IV iron dose was 111 (49.5-197) mg/month. There were no significant differences in age, body mass index, comorbidities, and laboratory parameters (except hemoglobin concentration) between responder groups (Table 1) .
Hemoglobin Response
The AUC-HGB distribution for each responder group is shown in Figure 1B . The median (range) AUC-HGBs for each group were: 4.45 (0-20) g · y/dL in the excellent responder group; 48.2 (26-65) g · y/dL in the good responder group; 101 (76-109) g · y/dL in the fair responder group; and 201 (123-528) g · y/dL in the poor responder group. Figure 2 shows the hemoglobin response over a 12-month period with deviations above and below the target range for a representative patient from each responder group. Linear regression analysis revealed that the patient's baseline characteristics, including age, sex, ethnicity, and BMI, did not have a significant impact on AUC-HGB. Forty-two hospitalizations occurred, more of which were in the lower responder groups (n = 28 in fair and poor groups compared to n = 14 in the excellent and good groups; P = .025). Infectious causes of hospitalization occurred only in the poor responder group (35% of causes in that group) whereas cardiac causes of hospitalization were more common in excellent and good responder groups (50% of causes in those groups; see Table 1 ). Five patients died over 2 years of follow-up; 3 were in the poor responder group, 1 in the fair responder group, and 1 in the good responder group.
The frequency, duration, and amplitude of hemoglobin deviations outside the target range in each responder group are summarized in Table 2 . The excellent responder group maintained hemoglobin concentrations within the target range over nearly the entire 12-month period, while the poor responder group had a mean of 2.58 hemoglobin deviations per year at a mean hemoglobin amplitude of 1.21 g/dL for a mean duration of 5 months (146 days) during the 12-month period. Similar to the total population, hemoglobin concentrations below the lower limit of the target range were significantly higher in number and amplitude and of longer duration compared to deviations above the upper limit of the target range for all 4 responder groups.
As shown in Figure 1 , both the erythropoietin resistance index (panel C) and time within therapeutic range (panel D) were significantly correlated with AUC-HGB. There was a significant negative correlation between time within therapeutic range and AUC-HGB (r = -.92; P < .001), while there was a significant positive correlation between erythropoietin resistance index and AUC-HGB (r = .70; P < .001). The mean time within therapeutic range and erythropoietin resistance index values in the response groups are summarized in Table 2 . Erythropoietin resistance index and time within therapeutic range were significantly lower (P < .01) and higher (P < .001), respectively, in the excellent responder group compared to the remaining responder groups. There were also strong correlations between hemoglobin concentration and time within therapeutic range (r = .83; P < .001), erythropoietin resistance index (r = -.66; P < .01), and AUC-HGB (r = -.85; P < .01) as displayed in Figure S1 .
Erythropoiesis-Stimulating Agent Administration
As shown in Table 1 , poor responders received significantly higher epoetin alfa doses but with a similar number of dose adjustments compared to other responder groups. Epoetin alfa dose was also significantly correlated with the erythropoietin resistance index (r = .98; < 0.01) and time within therapeutic range (r = -.65; P < .01) as demonstrated in Figure S1 . The monthly weight-adjusted epoetin alfa doses between excellent and poor responders are compared in Figure S2 . In the poor responder group, epoetin alfa doses higher than 600 U/kg/week were administered to 9 of 12 patients for at least 6 weeks and 5 of 12 patients for more than 5 months. In the excellent responder group, none of the patients received epoetin alfa doses higher than 600 U/kg/week.
Iron Administration
Median (IQR) monthly IV iron doses in each group are summarized in Table 1 . No statistically significant differences were detected between the responder groups with respect to monthly IV iron dose. However, 8 of 12 patients in the poor responder group and 1 patient in the excellent responder group received monthly IV iron doses >1000 mg/month for at least 1 month ( Figure S3 ). 
Covariable Results
There were no correlations between AUC-HGB, laboratory, and dialysis parameters except hemoglobin.
Discussion
The new AUC-HGB metric is a valid assessment of hemoglobin variability in response to epoetin alfa therapy. This novel quantitative approach uses an areabased method to characterize the temporal-spatial nature of hemoglobin deviations outside of the target range (AUC-HGB).
In the present study, the new AUC-HGB metric was compared to the time within therapeutic range. While time within therapeutic range is conventionally used to assess international normalized ratio data over time for warfarin therapy, De Nicola et al 17 described the use of the time within therapeutic range metric using linear interpolation in chronic kidney disease patients receiving an erythropoiesis-stimulating agent. Both metrics evaluate hemoglobin concentrations within the target range ( Figure 1C) ; however, AUC-HGB additionally quantifies hemoglobin deviations outside the range. A strong correlation between AUC-HGB and time within therapeutic range indicates internal validity of this new metric.
Erythropoiesis-stimulating agent resistance is an important consideration, especially in patients who spend a considerable amount time out of range. Patient factors such as iron and vitamin B 12 status, inflammation, type of dialysis, comorbidities, and concomitant medications may affect erythropoiesisstimulating agent responsiveness. 23 The erythropoietin resistance index is limited because it primarily focuses on the erythropoiesis-stimulating agent dose administered over time and does not consistently relate to the observed outcome. 19, 24 For example, in a large study of hemodialysis patients (n = 9368), the erythropoietin resistance index was representative of only the weight-based epoetin dose, 19 with a strong positive linear correlation between the erythropoietin resistance index and epoetin dose (r 2 = .97-.98) and no correlation between the erythropoietin resistance index and hemoglobin concentration (r 2 = .12). Our study revealed that AUC-HGB was significantly and highly correlated with the erythropoietin resistance index ( Figure 1D ), which indicates the external validity of the new metric. More importantly, AUC-HGB demonstrated a relationship with other variables (ie, more frequent iron administration, hospitalization, and higher epoetin alfa dose) known to be associated with erythropoiesis-stimulating agent resistance ( Table 1) . The poor responder group had the highest rate of infectious hospitalizations, which may indicate higher inflammatory burden and erythropoiesis-stimulating Metrics include mean hemoglobin (g/dL), mean AUC-HGB (g · d/dL) outside the defined target window for hemoglobin in either direction upward (above the upper limit of the target window) or downward (below the lower limit of the target window), the number of deviations outside the target range, amplitude of these deviations (g/dL), erythropoietin resistance index (U/kg/week/g/dL), and time within therapeutic range (%). AUC-HGB: Area under the curve versus time for hemoglobin deviations outside of target range (10-12g/dL). P-values reflect comparisons between the excellent responder (the lowest AUC-HGB) group and the poor responder (the highest AUC-HGB) group. a Upward deviation is defined as a hemoglobin concentration above the upper target range limit (12 g/dL) (refer to Figure 1A ). b Downward deviation is defined as a hemoglobin concentration below the lower target range limit (10 g/dL) (refer to Figure 1A ).
agent resistance. These findings may reflect that AUC-HGB is a possible marker of erythropoiesis-stimulating agent resistance. However, this hypothesis warrants further investigation to evaluate associations with erythropoiesis-stimulating agent resistance in a larger population. Although previous studies have suggested that hemoglobin variability is caused by frequent erythropoiesis-stimulating agent dose adjustments, 15, 25 we did not see any association between these 2 variables. Our results indicated fewer hemoglobin deviations outside the target range (1.67 vs 3.1 times per patient per year) and more epoetin alfa dose changes (10 vs 6.3 times per patient per year) than those reported by Fishbane and Berns. 15 In another study of Australian (n = 56) and UK (n = 154) hemodialysis patients by Roche et al, 25 the number of hemoglobin deviations outside the target range was similar (2.68 [Australian] and 3.18 [UK] vs 3.1 times per patient per year), but there were fewer epoetin alfa dose adjustments per year on average than those reported by Fishbane and Berns (2 [both in Australia and the United Kingdom] vs 6.3 times per patient per year). This discrepancy could be due to the different methods used to determine the number of deviations outside the target range: Fishbane and Berns counted when the hemoglobin amplitude was >1.5 g/dL, while Roche et al defined hemoglobin deviations as a hemoglobin concentration outside the target range, but the defined lower end of the target range was higher and the target window was narrower in Australia (11-12 g/dL) and the United Kingdom (11-12.5 g/dL) compared to our study (10-12 g/dL). The utility of the AUG-HGB metric is that it can easily accommodate different target hemoglobin ranges (eg, 10-11g/dL) and quantitates any deviation from the target range, regardless of amplitude.
In a retrospective observational study of hemodialysis patients (n = 987), Berns et al 26 observed a high correlation between mean serum ferritin and hemoglobin variability. Although not statistically significant, this finding is consistent with our study in which the poor responder group had a higher ferritin concentration and the highest hemoglobin variability (Table 1) . Additionally, this group had lower hemoglobin concentrations despite having received higher epoetin alfa and iron doses than the other groups (Table 1, Figure S1 ).
There are limitations to this study, primarily its retrospective nature. The sample size was small, but the rigorous quality control during data collection and frequent laboratory assessment of this hemodialysis population helped mitigate inaccurate or missing data. The purpose of this study was to characterize a new metric and validate it against existing erythropoiesisstimulating agent response metrics of erythropoietin resistance index and time within therapeutic range. While the sample size was small, intensive data collection of 1368 hemoglobin observations over the study period was adequate for this preliminary study to validate the new AUC-HGB metric. Finally, we utilized a target hemoglobin range of 10 to 12 g/dL based on the US and international guidelines for erythropoiesisstimulating agent monitoring. [10] [11] [12] [13] [14] The advantage of the AUC-HGB metric is that it can easily accommodate any target hemoglobin range (eg, 10-11 g/dL). It can also focus solely on downward hemoglobin deviation (Table 2) , which is associated with increased mortality. 27 It is important to consider that the thresholds we propose in this study are empirical and based on quartile analysis of the AUC-HGB in a small sample of ESRD patients over a 1-year period. Larger-scale analysis should be conducted to provide a more robust threshold for characterization of response categories over different time periods. With these limitations in mind, we suggest that a HGB-AUC of 80 g·y/dL (equivalent to 20 g·/3 months/dL) be considered an initial threshold for good vs poor response to erythropoiesis-stimulating agents.
Conclusions
AUC-HGB is a new method to assess erythropoiesisstimulating agent response. Compared to conventional metrics, AUC-HGB is internally and externally valid. Future large-scale analyses should define optimal thresholds of AUC-HGB for responder status.
